🔴 Neumora Therapeutics is trading 5% down today after reporting a $43.1 million net loss

Neumora Therapeutics is trading at $1.64, down -5.20%, after reporting second-quarter results and appointing Joshua Pinto as CEO.

• Reported a $43.1 million second-quarter net loss
• Cash declined to $116.8 million, with the operating plan funded into Q3 2027
• Cost reductions and a strategic focus on obesity and Alzheimer’s programs may be driving investor reassessment of the pipeline